These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25255395)

  • 1. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension.
    Chung O; Vongpatanasin W; Bonaventura K; Lotan Y; Sohns C; Haverkamp W; Dorenkamp M
    J Hypertens; 2014 Dec; 32(12):2411-21; discussion 2421. PubMed ID: 25255395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
    Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
    Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
    Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
    PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension.
    Cheng HM; Pearson A; Sung SH; Yu WC; Chen CH; Karnon J
    Am J Hypertens; 2015 May; 28(5):604-14. PubMed ID: 25430695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
    Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.
    Conti RM; Padula WV; Becker RV; Salamone S
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1077-1085. PubMed ID: 34337991
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost effectiveness of an adherence-improving programme in hypertensive patients.
    Brunenberg DE; Wetzels GE; Nelemans PJ; Dirksen CD; Severens JL; Stoffers HE; Schouten JS; Prins MH; de Leeuw PW; Joore MA
    Pharmacoeconomics; 2007; 25(3):239-51. PubMed ID: 17335309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.
    van Schoonhoven AV; van Asselt ADI; Tomaszewski M; Patel P; Khunti K; Gupta P; Postma MJ
    Hypertension; 2018 Nov; 72(5):1117-1124. PubMed ID: 30354817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension.
    Velasco A; Chung O; Raza F; Pandey A; Brinker S; Arbique D; Price A; Lotan Y; Das SR; Vongpatanasin W
    J Clin Hypertens (Greenwich); 2015 Sep; 17(9):713-9. PubMed ID: 25917401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?
    Mar J; Rodríguez-Artalejo F
    J Hypertens; 2001 Jan; 19(1):149-55. PubMed ID: 11204296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4).
    Monahan M; Jowett S; Nickless A; Franssen M; Grant S; Greenfield S; Hobbs FDR; Hodgkinson J; Mant J; McManus RJ
    Hypertension; 2019 Jun; 73(6):1231-1239. PubMed ID: 31067190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of renin-guided treatment of hypertension.
    Smith SM; Campbell JD
    Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
    Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
    Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.